🇺🇸 boceprevir (SCH 503034) in United States

75 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 75

Most-reported reactions

1. Anaemia — 17 reports (22.67%)
2. Pyrexia — 10 reports (13.33%)
3. Asthenia — 9 reports (12%)
4. Neutropenia — 7 reports (9.33%)
5. Diarrhoea — 6 reports (8%)
6. White Blood Cell Count Decreased — 6 reports (8%)
7. Ascites — 5 reports (6.67%)
8. Haemoglobin Decreased — 5 reports (6.67%)
9. Pancytopenia — 5 reports (6.67%)
10. Vomiting — 5 reports (6.67%)

Source database →

Frequently asked questions

Is boceprevir (SCH 503034) approved in United States?

boceprevir (SCH 503034) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for boceprevir (SCH 503034) in United States?

Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.